The NCPE recommends that nivolumab in combination with ipilimumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

The NCPE recommends that dupilumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

The NCPE recommends midostaurin (Rydapt®) for AML not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. *

The NCPE recommends that venetoclax in combination with rituximab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*

The NCPE recommends that nivolumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*

Chronic Migraine: The NCPE recommends that erenumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*

Episodic Migraine: The NCPE recommends that erenumab not be considered for reimbursement.*

The NCPE recommends that darvadstrocel (Alofisel®) not be considered for reimbursement.*

The NCPE recommends that tisagenlecleucel (Kymriah®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.* 

The NCPE recommends that tisagenlecleucel (Kymriah®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.* 

The NCPE recommends that pembrolizumab (Keytruda®), prescribed in combination with platinum chemotherapy plus pemetrexed for the first line treatment of non-squamous NSCLC, be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.